Building on research at the Gladstone Institutes, Tenaya Therapeutics, a new biopharmaceutical company, will concentrate on regenerative medicine and drug discovery for cardiovascular diseases. The new company is supported by $50 million in Series A financing from The Column Group. JJ Kang, Ph.D., an associate at The Column Group, is the president of the new company.

Tenaya is the first company to be created from BioFulcrum, the entrepreneurial initiative within Gladstone, that started in January, 2015. The new company plans to leverage Gladstone’s work with cellular reprogramming in their research, including regenerating heart muscles and creating stem-cell derived heart models for pharmaceutical development.

Previous articleLonza Sells Peptides Operations to PolyPeptide Group
Next articleLive Brain Imaging Shows Cerebral Malaria’s Detrimental Effects